Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (16537)	1/12/2004 1:11:34 AM
From: Bluegreen	Read Replies (1) \| Respond to of 17367

George, meet Lyle, notice how long he has been taking the MIRACLE biologic Raptiva.>>>>>>>>>>>>>>>>>http://www.gene.com/gene/products/profiles/raptiva.jsp

To: aknahow who wrote (16537)	1/18/2004 10:17:29 PM
From: Lance Bredvold	Respond to of 17367

Contra Costa Times Jan 6 snip. Now I see why so often people insert a request for understanding if the item has already been posted. But I did not see or remember it. contracostatimes.com Biotechnology XOMA Ltd. (XOMA), a Berkeley-based company, announced that it has entered a licensing and product development agreement with Diversa Corporation (DVSA) of San Diego. Diversa gains access to XOMA's antibody expression technology for developing antibody products independently and with collaborators, and an option to a license for the production of antibodies under the XOMA patents. XOMA will receive a license fee and potential future milestone and royalty payments. The two companies also plan to work together to discover and develop antibodies for auto-immune-related diseases. Diversa will receive research funding and is entitled to receive milestones and royalties on any drugs developed under the agreement.